Impact of the PET in the Diagnosis Strategy of FUO or Inflammatory Syndrome in Immunocompetent Patients FUO-TEP
NCT01200771 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 116
Last updated 2025-07-20
Summary
Fever of unknown origin (FUO) and chronic inflammatory syndrome could be seen in many affections. The diagnostic process is still a challenge and could not be specified yet after several clinical studies performed by trained teams using two levels diagnostic procedures. For this reason, the diagnosis involves many additional and expensive tests such as computed tomography (CT scan), scintigraphic imaging, endoscopy, biopsy. There is no evidence-based recommendation for the diagnostic work-up of FUO or chronic inflammatory syndrome. Positron emission tomography with 2-\[18F\] fluoro-2-deoxy-D-glucose combined with CT scan (FDG-PET/CT) is widely used in malignant diseases and seems to be promising for the diagnosis of inflammatory disorders. Its role has not been yet clearly defined in the investigation of FUO and chronic inflammatory syndrome.
Conditions
Interventions
- PROCEDURE
-
TEP
Intravenous injection of glucose labeled Fluor 18. The patient remains fasted at least 6 hours before the start of the examination. The review lasted 1 hour, during wich the patient should not move.
Sponsors & Collaborators
-
University Hospital, Limoges
lead OTHER
Principal Investigators
-
Kim LY, MD · University Hospital, Limoges
Study Design
- Allocation
- NA
- Purpose
- DIAGNOSTIC
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2008-05-31
- Primary Completion
- 2012-05-31
- Completion
- 2014-02-28
Countries
- France
Study Locations
More Related Trials
-
68Gallium-FAPI46 PET/CT Imaging in Chronic Inflammatory and Fibrotic Diseases
NCT06275477 ·Status: RECRUITING ·Phase: NA
-
Creation of a Normal Database for FluoroDeoxyGlucose-Positron Emission Tomography (FDG-PET) Neurological Examinations
NCT02858167 ·Status: COMPLETED ·Phase: NA
-
Fluoroglutamine PET/CT in Imaging Patients With Malignant Tumor
NCT03721055 ·Status: UNKNOWN ·Phase: NA
-
Benefits Study of Respiratory-gated PET Acquisition in Lung Disease
NCT01812031 ·Status: COMPLETED ·Phase: NA
-
18F-FDS PET/CT in Healthy Volunteers and Patients With Suspected Infection
NCT02450942 ·Status: UNKNOWN ·Phase: EARLY_PHASE1
-
18F-Fluoro-Ethyl-Tyrosine (FET) Positron Emission Tomography (PET) and Grading Glioma
NCT04001257 ·Status: COMPLETED
-
The Use of FDG-PET in Patient With Hodgkin Lymphoma: a Population Based Study From Northern Italy
NCT01248000 ·Status: COMPLETED
-
Benefits Study of Respiratory-gated Positron Emission Tomography Acquisitions of the Liver
NCT01219985 ·Status: COMPLETED ·Phase: NA
-
18F-FDG PET/CT-based Prognostic Model for Predicting Outcome in Patients With Diffuse Large B-cell Lymphoma
NCT02928861 ·Status: UNKNOWN ·Phase: NA
-
Assessment of [18F]FLT-PET Imaging for Diagnosis and Prognosis of Brain Tumors
NCT00850278 ·Status: COMPLETED ·Phase: NA
-
FDG-Positron Emission Tomography (PET)/CT In the Evaluation of Persistent Febrile Neutropenia in Cancer Patients
NCT00707213 ·Status: TERMINATED ·Phase: PHASE1
-
18F-FDG PET/CT-based Prognostic Model for Predicting Outcome in Patients With Peripheral T-cell Lymphoma
NCT03051581 ·Status: UNKNOWN ·Phase: NA
-
Fluorodeoxyglucose-Positron Emission Tomography (FDG-PET) to Evaluate Autoimmune Lymphoproliferative Syndrome (ALPS) and ALPS-associated Lymphoma
NCT00068146 ·Status: COMPLETED
-
Positron Emission Tomography of Infection and Vasculitis
NCT01878721 ·Status: COMPLETED
-
PET/CT and Bacterial/Fungal PCR in High Risk Febrile Neutropenia
NCT03429387 ·Status: COMPLETED ·Phase: NA
-
Interest of a Systematic One-year Monitoring by 18F-FDG PET-CT
NCT04464590 ·Status: COMPLETED
-
Validation of the Analysis Methodology Behind the Use of Quantitative 18F-FDG PET/CT to Assess Lung Inflammation
NCT03312712 ·Status: UNKNOWN
-
Dynamic F-DOPA PET for Differential Diagnosis Between Recurrence and Radionecrosis of Brain Metastasis
NCT05762172 ·Status: COMPLETED ·Phase: NA
-
Determination of Molecular Status, the Efficacy and Safety of Fluorodeoxyglucose in PET-CT Imaging
NCT04943211 ·Status: RECRUITING ·Phase: PHASE3
-
Breast PET Feasibility
NCT03198442 ·Status: COMPLETED ·Phase: NA
-
Assessment of 4D 18F-FDG PET-CT in Radiotherapy for Non Small Cell Lung Cancers
NCT01421953 ·Status: COMPLETED ·Phase: NA
-
Correlation Between Various Adipokines and Vascular Inflammation Measured by Positron Emission Tomography (PET) With 18F-fluoro-deoxyglucose (FDG) (18FDG-PET)
NCT01150006 ·Status: COMPLETED
-
FDG-PET as an Imaging Modality to Diagnose and Risk Stratify Subclinical, Imaging Negative Ici-Myocarditis
NCT06566209 ·Status: TERMINATED
-
68Ga-NOTA Evans Blue PET/CT in Patients With Lymphatic System Related Diseases
NCT05140083 ·Status: UNKNOWN ·Phase: PHASE1
-
Defining PET / CT Protocols With Optimized F18-FDG (Fluorodeoxyglucose) Dose, Focusing on Reduced Radiation Dose and Improved Image Quality
NCT02378337 ·Status: COMPLETED